STEP-UP will test intensified radiotherapy for unresectable locally recurrent rectal cancer

The 30-patient STEP-UP study will assess severe toxicity after dose-escalated SBRT, hyperfractionated reirradiation or chemoradiotherapy for unresectable rectal recurrence.

KEY POINTS

  • STEP-UP (NCT07721181) is a prospective, multicenter, open-label, single-arm feasibility study developed in the Netherlands for patients with unresectable or medically inoperable locally recurrent rectal cancer. The study plans to enroll 30 patients across seven radiotherapy centers, including individuals without distant metastases or with limited metastatic disease not requiring immediate systemic treatment. Participants will enter one of three treatment pathways according to previous irradiation and clinical suitability, with at least 10 patients planned per pathway.
  • Previously irradiated patients with suitable anatomy will receive stereotactic reirradiation to 45 Gy in five fractions (9 Gy per fraction). Eligibility for re-SBRT requires a well-demarcated recurrent lesion measuring less than 6 cm, without direct invasion of luminal organs and without clinically significant persistent late radiation toxicity. SBRT planning will incorporate cumulative OAR dose evaluation and permit reduced target coverage when necessary to satisfy safety constraints.
  • Patients previously irradiated but unsuitable for re-SBRT because of tumor size, anatomical involvement or dose limitations will receive hyperfractionated chemoradiotherapy with 50.4 Gy in 42 fractions of 1.2 Gy twice daily. Fractions must be separated by at least six hours, and concurrent capecitabine 825 mg/m² twice daily on radiotherapy days is planned. The protocol permits smaller PTV margins with online adaptation and recommends avoiding substantial hotspots in previously irradiated organs.
  • Patients without previous pelvic radiotherapy will receive 50 Gy in 25 fractions to the elective volume, with a simultaneous integrated boost to 65 Gy in 25 fractions (2.6 Gy per fraction) for gross recurrent disease. Concurrent capecitabine will also be administered in this group. The resulting tumor boost corresponds to approximately 70.6 Gy EQD2 using α/β = 5 Gy, providing a biological rationale for dose escalation without requiring a separate sequential boost phase.
  • For reirradiation, the protocol incorporates assumed normal-tissue recovery when estimating cumulative OAR exposure: 30% recovery of the original radiation dose after a 6–18-month interval and 50% recovery after more than 18 months. These are protocol-defined planning assumptions, not universally validated biological recovery factors. All treatment plans will undergo central quality assurance, including prospective review of target delineation and dose distributions before treatment begins.
  • The primary endpoint is feasibility, defined as no more than seven of 30 patients (approximately 23%) experiencing qualifying acute grade ≥3 radiotherapy-related adverse events. The protocol specifies exclusions for predefined expected treatment-related toxicities within this feasibility assessment and includes independent monitoring by a Data Safety Monitoring Board. A treatment-related grade 5 event triggers immediate review and temporary suspension of the affected treatment pathway; two such events require permanent closure of that pathway.
  • Secondary endpoints include late grade ≥3 toxicity, symptom control, quality of life, treatment completion, and disease-control and survival outcomes through three years. Patient-reported outcomes will be assessed using EORTC QLQ-C30, QLQ-CR29 and EQ-5D-5L at baseline and at 3, 6, 12, 24 and 36 months following RT. Recruitment is expected to continue through approximately 2029, and the study is not powered to demonstrate efficacy or compare the three treatment strategies; no patient results are reported in this protocol publication.

CLINICAL TAKEAWAY

STEP-UP addresses an important clinical gap for patients with locally recurrent rectal cancer who cannot undergo curative surgery, evaluating intensified radiotherapy approaches according to previous treatment exposure and recurrence anatomy. Its main contribution is a structured prospective framework for assessing feasibility and severe toxicity, while any improvement in local control, symptom burden or survival remains unproven until clinical results become available.

SOURCE

Clinical and Translational Radiation Oncology

Browse more research Suggest a correction